Project Grant R21AI202489
Award Date 8/20/26
Completion Date 7/31/28
Dollars Obligated $163K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $251,324 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered organ transplants resistant to antibody-mediated rejection through synthetic biology platforms. The research focuses on designing signal-inducible, drug-controllable endopeptidases for localized antibody degradation within transplanted tissue. The award funds...
- The National Institute of Allergy and Infectious Diseases awarded New York University $230,340 on September 30, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antibody-based therapies that block pathogenic donor-specific antibody (DSA) responses in transplant rejection. The three-year training plan, performed at New York University School of Medicine in New York, New York, aims to engineer recombinant antibodies from pathogenic DSAs into blocking...
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $847,299 on August 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immunomodulatory mechanisms in allograft rejection. The project, titled "Regulation of Alloimmunity by Intragraft Endothelial Cells," examines how graft microvascular endothelial cells suppress alloimmune responses during transplant rejection. The research will characterize...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $750,787 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate central memory stem-cell-like follicular helper T cells (CTFH) and their contribution to durable donor-specific anti-HLA antibodies (DSA) and chronic antibody-mediated rejection (ABMR) in kidney transplant recipients. The research addresses mechanisms of chronic rejection in solid organ...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $1.228 million on June 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop donor-specific transplant tolerance strategies using immune reset approaches in a rhesus monkey kidney allograft model. The research combines T regulatory cell–promoting strategies, including an IL-2 mutein (MIL-2) administered in combination with rapamycin, anti-CD154 monoclonal antibody, IL-6...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $444,125 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to accelerate T cell immune reconstitution following cultured thymus tissue implantation (CTTI). The research addresses the urgent clinical need to speed immune recovery after thymus transplantation, which currently risks early post-transplant deaths from infection before immune reconstitution occurs. Duke's prior...
- The National Institute of Allergy and Infectious Diseases awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $690,359 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the regulation of donor-specific antibody production in kidney transplantation. The research addresses antibody-mediated rejection (ABMR), a leading cause of renal transplant loss, by examining the role of lymphocyte activation gene 3...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $444,125 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through July 31, 2027. The award supports investigator-initiated biomedical research focused on developing and evaluating therapeutic interventions for xenotransplantation rejection. Specifically, the...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $597,613 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop ex vivo delivery of viral-mediated gene therapy for ameliorating post-transplant rejection in lung transplantation. The research develops adeno-associated virus (AAV) vector delivery during normothermic ex vivo lung perfusion (EVLP) to genetically modify donor lung grafts. The project addresses high...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $161,500 under Project Grant R03AI195794 on April 1, 2026, to develop new genetic tools for selective targeting of plasma cells. The recipient will develop new Cre and CreERT2 mouse models to enable gene targeting and tracing studies in plasma cells. Existing mouse models for plasma cell-selective genetic dissection have significant limitations due to leakiness into closely related cell lineages such as germinal...